UA100262C2 - Інгібітори активності протеїнтирозинкінази - Google Patents

Інгібітори активності протеїнтирозинкінази

Info

Publication number
UA100262C2
UA100262C2 UAA201013462A UAA201013462A UA100262C2 UA 100262 C2 UA100262 C2 UA 100262C2 UA A201013462 A UAA201013462 A UA A201013462A UA A201013462 A UAA201013462 A UA A201013462A UA 100262 C2 UA100262 C2 UA 100262C2
Authority
UA
Ukraine
Prior art keywords
tyrosine kinase
kinase activity
protein tyrosine
inhibitors
compounds
Prior art date
Application number
UAA201013462A
Other languages
English (en)
Russian (ru)
Inventor
Мішель Манніон
Мишель Маннион
Стефан Раппель
Стефен Вільям Кларідж
Стефен Вильям Кларидж
Фредерік Годетте
Фредерик Годетте
Ліжє Зан
Лиже Зан
Любомір Ісаковіч
Любомир ИСАКОВИЧ
Оскар Маріо Сааведра
Оскар Марио СААВЕДРА
Тесююкі Уно
Тесююки Уно
Масаші Кішіда
Масаши КИШИДА
Аркадій Вайсбург
Аркадий Вайсбург
Original Assignee
Метилген Інк.
Метилген Инк.
Оцука Фармас'Ютікел Ко., Лтд.
Оцука Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Метилген Інк., Метилген Инк., Оцука Фармас'Ютікел Ко., Лтд., Оцука Фармасьютикал Ко., Лтд. filed Critical Метилген Інк.
Publication of UA100262C2 publication Critical patent/UA100262C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Abstract

Цей винахід стосується сполук, які інгібують активність протеїнтирозинкіназ. Зокрема, винахід стосується сполук, які інгібують активність протеїнтирозинкіназ рецепторів факторів росту, що приводить до інгібування сигналізації рецепторів, наприклад інгібування сигналізації рецепторів VEGF. Винахід також пропонує сполуки, композиції та способи лікування хвороб та станів розростання клітин й офтальмологічних хвороб, розладів та станів.
UAA201013462A 2008-03-05 2009-02-27 Інгібітори активності протеїнтирозинкінази UA100262C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3400508P 2008-03-05 2008-03-05

Publications (1)

Publication Number Publication Date
UA100262C2 true UA100262C2 (uk) 2012-12-10

Family

ID=41055503

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA201013462A UA100262C2 (uk) 2008-03-05 2009-02-27 Інгібітори активності протеїнтирозинкінази
UAA201011785A UA101362C2 (en) 2008-03-05 2009-02-27 Protein tyrosine kinase activity inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA201011785A UA101362C2 (en) 2008-03-05 2009-02-27 Protein tyrosine kinase activity inhibitors

Country Status (19)

Country Link
US (3) US8729268B2 (uk)
EP (2) EP2262815A4 (uk)
JP (2) JP2011513339A (uk)
KR (2) KR20100137495A (uk)
CN (2) CN102161663B (uk)
AR (2) AR070539A1 (uk)
AU (2) AU2009221583B2 (uk)
BR (2) BRPI0923670A2 (uk)
CA (2) CA2717816A1 (uk)
CO (1) CO6290684A2 (uk)
IL (2) IL207946A0 (uk)
MX (1) MX2010009729A (uk)
NZ (2) NZ589336A (uk)
RU (2) RU2498988C2 (uk)
SG (1) SG182146A1 (uk)
TW (2) TWI438205B (uk)
UA (2) UA100262C2 (uk)
WO (1) WO2009109035A1 (uk)
ZA (2) ZA201005868B (uk)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ589336A (en) * 2008-03-05 2011-12-22 Methylgene Inc Pyridine derivatives as inhibitors of protein tyrosine kinase activity
EP2473501B1 (en) 2009-09-03 2019-02-20 Allergan, Inc. Compounds as tyrosine kinase modulators
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
AU2011241422B2 (en) * 2010-04-16 2015-05-07 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
TWI482770B (zh) * 2010-06-09 2015-05-01 Abbvie Bahamas Ltd 結晶型激酶抑制劑
TWI492949B (zh) * 2010-06-09 2015-07-21 Abbvie Bahamas Ltd 結晶型激酶抑制劑
EP2580221B1 (en) * 2010-06-09 2015-10-21 AbbVie Bahamas Ltd. Crystalline forms of kinase inhibitors
CA2809333C (en) * 2010-08-27 2018-09-25 Merck Patent Gmbh Furopyridine derivatives
EP3590925B1 (en) * 2010-09-17 2022-03-30 Purdue Pharma L.P. Pyridine compounds and the uses thereof
BRPI1004176A2 (pt) * 2010-10-25 2015-08-11 Univ Rio De Janeiro Compostos aril e/ou hetero aril uréias funcionalizados; processo de síntese desses composto; composição farmacêutica contendo tais compostos e usos
US20130096135A1 (en) * 2011-09-30 2013-04-18 Methylgene Inc. Selected Inhibitors of Protein Tyrosine Kinase Activity
US20130090327A1 (en) * 2011-09-30 2013-04-11 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
KR20170093943A (ko) * 2014-12-09 2017-08-16 애브비 인코포레이티드 낮은 세포 투과성을 갖는 bcl xl 억제 화합물 및 이를 포함하는 항체 약물 접합체
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
KR20220045189A (ko) 2019-08-12 2022-04-12 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양을 치료하는 방법
KR20220123057A (ko) 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 비정질 키나아제 억제제 제형 및 이의 사용 방법
CA3163051A1 (en) 2019-12-30 2021-07-08 Michael D. Kaufman Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
TW202342426A (zh) * 2022-02-15 2023-11-01 大陸商百濟神州（蘇州）生物科技有限公司 N-[(6-溴吡啶-3-基)甲基]-2-甲氧基乙烷-1-胺鹽及其製備方法
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019A (en) * 1850-01-15 Improvement in obstetrical supporters
US7000A (en) * 1850-01-08 Smut-machine
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
SK6652000A3 (en) 1997-11-11 2002-05-09 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
KR20010052570A (ko) 1998-06-04 2001-06-25 스티븐 에프. 웨인스톡 세포 유착을 억제하는 소염성 화합물
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1287001B1 (en) 2000-06-06 2004-09-29 Pfizer Products Inc. Thiophene derivatives useful as anticancer agents
US20020004511A1 (en) 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
NZ525324A (en) * 2000-10-20 2005-03-24 Eisai Co Ltd Nitrogenous aromatic ring compounds
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000194A2 (en) 2001-06-21 2003-01-03 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
BR0308162A (pt) 2002-03-01 2004-12-07 Pfizer Derivados de indolil-uréia de tienopiridinas úteis como agentes antiangiogênicos e métodos para o seu uso
US20030199525A1 (en) 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
WO2005009348A2 (en) 2003-06-25 2005-02-03 Ariad Pharmaceuticals, Inc. Substituted purine derivatives
ATE412655T1 (de) 2003-08-29 2008-11-15 Pfizer Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
US7581674B2 (en) 2003-11-21 2009-09-01 Charles Cohen Financial transaction system and method
EP1711495A2 (en) 2004-01-23 2006-10-18 Amgen Inc. Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
WO2005121125A1 (en) 2004-06-09 2005-12-22 Pfizer Inc. Ether-linked heteroaryl compounds
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
AU2005270068B2 (en) 2004-07-02 2012-04-19 Exelixis, Inc. C-Met modulators and method of use
KR20070057792A (ko) 2004-07-16 2007-06-07 선에시스 파마슈티컬스 인코포레이티드 오로라 키나아제 저해물질로서 유용한 티에노피리미딘
RU2007107167A (ru) 2004-07-30 2008-09-10 Метилджин, Инк. (Ca) Ингибиторы передачи сигнала рецептора vegf и рецептора hgf
EP1827434B1 (en) 2004-11-30 2014-01-15 Amgen Inc. Quinolines and quinazoline analogs and their use as medicaments for treating cancer
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
WO2006108059A1 (en) 2005-04-06 2006-10-12 Exelixis, Inc. C-met modulators and methods of use
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
CN101248080B (zh) 2005-05-20 2012-09-05 梅特希尔基因公司 Vegf受体和hgf受体信号的抑制剂
WO2008041053A2 (en) 2005-05-20 2008-04-10 Methylgene, Inc. Inhibitors of vegf receptor and hgf receptor signaling
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
WO2008063202A2 (en) * 2006-01-30 2008-05-29 Array Biopharma Inc. Heterobicyclic thiophene compounds for the treatment of cancer
US20080064718A1 (en) 2006-03-22 2008-03-13 Saavedra Oscar M Inhibitors of protein tyrosine kinase activity
US7298968B1 (en) * 2007-01-05 2007-11-20 Rheem Manufacturing Company Pumpless combination instantaneous/storage water heater system
EP2183254B1 (en) * 2007-08-29 2017-06-21 MethylGene Inc. Inhibitors of protein tyrosine kinase activity
NZ589336A (en) * 2008-03-05 2011-12-22 Methylgene Inc Pyridine derivatives as inhibitors of protein tyrosine kinase activity
AU2011241422B2 (en) * 2010-04-16 2015-05-07 Methylgene Inc. Inhibitors of protein tyrosine kinase activity

Also Published As

Publication number Publication date
RU2533827C2 (ru) 2014-11-20
CN102015723A (zh) 2011-04-13
JP5661485B2 (ja) 2015-01-28
US8759522B2 (en) 2014-06-24
AU2009221583A1 (en) 2009-09-11
BRPI0923670A2 (pt) 2013-07-30
JP2011513339A (ja) 2011-04-28
EP2262815A1 (en) 2010-12-22
RU2010145459A (ru) 2012-05-20
SG182146A1 (en) 2012-07-30
RU2010140668A (ru) 2012-04-10
KR20100132068A (ko) 2010-12-16
CN102161663A (zh) 2011-08-24
CA2717816A1 (en) 2009-09-11
US20110077240A1 (en) 2011-03-31
AR079208A2 (es) 2012-01-04
AU2009221583A2 (en) 2011-02-03
TW200940549A (en) 2009-10-01
AU2010246540B2 (en) 2013-02-28
RU2498988C2 (ru) 2013-11-20
NZ589336A (en) 2011-12-22
EP2262815A4 (en) 2012-04-11
US20140179632A1 (en) 2014-06-26
CN102015723B (zh) 2014-07-30
UA101362C2 (en) 2013-03-25
AR070539A1 (es) 2010-04-14
ZA201005868B (en) 2011-08-31
CN102161663B (zh) 2014-03-19
AU2009221583B2 (en) 2013-06-20
BRPI0908573A2 (pt) 2012-12-25
CA2763168A1 (en) 2009-09-11
TW201113288A (en) 2011-04-16
KR20100137495A (ko) 2010-12-30
EP2332536A1 (en) 2011-06-15
US8729268B2 (en) 2014-05-20
IL208882A0 (en) 2011-07-31
CO6290684A2 (es) 2011-06-20
IL207946A0 (en) 2010-12-30
NZ588355A (en) 2012-03-30
US20110098293A1 (en) 2011-04-28
AU2010246540A1 (en) 2010-12-23
MX2010009729A (es) 2010-12-21
ZA201007517B (en) 2012-01-25
JP2011105735A (ja) 2011-06-02
WO2009109035A1 (en) 2009-09-11
TWI438205B (zh) 2014-05-21

Similar Documents

Publication Publication Date Title
UA100262C2 (uk) Інгібітори активності протеїнтирозинкінази
WO2008035209A3 (en) Quinoline and quinazoline derivatives as inhibitors of protein tyrosine kinase activity
MY157319A (en) Inhibitors of protein tyrosine kinase activity
WO2007149427A3 (en) Tyrosine kinase inhibitors
PH12020551208A1 (en) Compounds for the treatment of kinase-dependent disorders
SI1896421T1 (sl) Benzocikloheptapiridini kot inhibitorji receptorjev tirozin kinaze met
MX2007014616A (es) Inhibidores de señalizacion del receptor del factor a de crecimiento endotelial vascular y del receptor del factor de crecimiento de hepatocitos.
WO2010005876A3 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
NO20090608L (no) Tyrosinkinaseinhibitorer
JOP20120246B1 (ar) مركبات و تركيبات كمثبطات كيناز c-Kit
MY165728A (en) Selective glycosidase inhibitors and uses thereof
MY155621A (en) Axl antibodies
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
JO3002B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
MX2014002486A (es) Compuestos y composiciones como inhibidores de cinasa pdgfr.
EP3715457A3 (en) Modulation of prekallikrein (pkk) expression
GB2460597A (en) N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
MX2011008602A (es) Metodos de tratamiento de condiciones relacionadas con el cabello.
WO2006086358A3 (en) Mitotic kinesin inhibitors
TW200738638A (en) Tyrosine kinase inhibitors
MX2010007669A (es) Metodos para inhibir la angiogenesis utilizando antagonistas de egfl8.
WO2014110198A3 (en) Therapeutic indications of kinase inhibitors